Clinical features of hemichoreahemiballism: A stroke-related movement disorder | Zendy

Nobuko Shiraiwa | Zendy; Sachiko Hoshino | Zendy; Go Saito | Zendy; Akira Tamaoka | Zendy; Norio Ohkoshi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Clinical features of hemichoreahemiballism: A stroke-related movement disorder

Author(s) -

Nobuko Shiraiwa,

Sachiko Hoshino,

Go Saito,

Akira Tamaoka,

Norio Ohkoshi

Publication year - 2020

Publication title -

neurology international

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.39

H-Index - 16

ISSN - 2035-8377

DOI - 10.4081/ni.2020.8328

Subject(s) - medicine , clonazepam , haloperidol , basal ganglia , dopaminergic , magnetic resonance imaging , stroke (engine) , pharmacotherapy , basal (medicine) , pathogenesis , diabetes mellitus , anesthesia , endocrinology , dopamine , central nervous system , radiology , mechanical engineering , engineering

We examined pathogenesis and clinical features of three hemichorea-hemiballism (HCHB) cases. We studied their age, magnetic resonance imaging results, vascular risk factors, management, and outcomes. One man and two women (aged 74-86 years) demonstrated acute onset of HCHB, lasting for at least several months. Patients had one or more vascular risk factors, including hypertension and diabetes. All patients presented subacute or old infarction in the basal ganglia with contralateral symptoms. We administered clonazepam (0.5-1 mg/day), haloperidol (0.375-0.75 mg/day), or both as necessary and observed symptom-control. Vascular lesions in the basal ganglia were a contributing factor. Symptoms were controlled using pharmacotherapy with gamma-aminobutyric acid-agonist (clonazepam) or anti-dopaminergic (haloperidol) medication.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research